Januvia And Onglyza In, Galvus Out, As Germany Evaluates Older Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s G-BA has panned Novartis’ Galvus, but retained Merck’s Januvia and Bristol/AstraZeneca’s Onglyza as it starts culling older drugs.